# Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07228832/  
OnCo record `nct07228832` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of CAPOX, FLOT in colorectal cancer, run by Summit Therapeutics, now recruiting.

## Summary

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07228832 by Summit Therapeutics, with 600 participants planned, started 2025-11-18 and due to reach its primary completion in 2028-05-31. Interventions recorded: Drug: Ivonescimab Injection, Drug: Bevacizumab Injection. Conditions listed: Metastatic Colorectal Cancer (CRC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07228832
- Phase: 3
- Setting: A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer
- Sponsor: Summit Therapeutics
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT07228832: https://clinicaltrials.gov/study/NCT07228832

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)](https://onco.cc/drugs/flot/)
- companies: [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07228832.json